Abg Innovation Capital Partners Iii Gp LTD Atea Pharmaceuticals, Inc. Transaction History

Abg Innovation Capital Partners Iii Gp LTD

$837,000
Q2 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $27 Million - $44.4 Million	-1,265,631 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $24.3 Million - $74.8 Million	1,265,631 New	1,265,631 $27.2 Million
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $109 Million - $233 Million	-2,639,178 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $69.6 Million - $110 Million	2,639,178 New	2,639,178 $110 Million

Others Institutions Holding AVIR

# of Institutions

111

Shares Held

51.2M

Call Options Held

71.8K

Put Options Held

318K

Black Rock Inc. New York, NY

9.12M
Shares

$30 Million
0.0% of portfolio
Bml Capital Management, LLC Zionsville, IN

6.38M
Shares

$21 Million
15.06% of portfolio
Eco R1 Capital, LLC San Francisco, CA

5.44M
Shares

$17.9 Million
0.64% of portfolio
Vanguard Group Inc Valley Forge, PA

4.72M
Shares

$15.5 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

4.48M
Shares

$14.7 Million
1.81% of portfolio

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $274M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Abg Innovation Capital Partners Iii Gp LTD, based on Form 13F filings with the SEC.

News

Stay updated on Abg Innovation Capital Partners Iii Gp LTD with notifications on news.

Account